---
title: "000028.SZ (000028.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000028.SZ/news.md"
symbol: "000028.SZ"
name: "000028.SZ"
parent: "https://longbridge.com/en/quote/000028.SZ.md"
datetime: "2026-03-10T03:05:06.379Z"
locales:
  - [en](https://longbridge.com/en/quote/000028.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000028.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000028.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/000028.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/000028.SZ/news.md)


# 000028.SZ (000028.SZ) — Related News

### [The world's first inactivated vaccine for fever with thrombocytopenia syndrome developed by SINOPHARM Group has been approved for clinical use](https://longbridge.com/en/news/278365258.md)
*2026-03-09T09:35:10.000Z*
> Recently, the National Key Laboratory for the Development of New Vaccines for Emerging Infectious Diseases, affiliated w

### [](https://longbridge.com/en/news/278005047.md)
*2026-03-06T00:31:09.000Z*
> The State Administration for Market Regulation released the list of unconditional approvals for operator concentration c

### [Sinopharm Accord: Currently, the business mainly focuses on the domestic market](https://longbridge.com/en/news/277896516.md)
*2026-03-05T07:21:51.000Z*
> On March 5th, Sinopharm Accord stated on the interactive platform that the company's business is currently mainly focuse

### [The Hong Kong Index closed at 26,765 points, up 175 points; the Hang Seng TECH Index closed at 5,260 points, down 10 points. HAIDILAO rose over 6%. HSBC HOLDINGS, TINGYI, SINOPHARM, TIME INTERCON, and WANGUO GOLD GP reached new highs with active trading](https://longbridge.com/en/news/276853786.md)
*2026-02-25T08:12:08.000Z*
> The Hang Seng Index closed at 26,765 points, up 175 points or 0.7%; the Hang Seng TECH Index reported 5,260 points, down

### [Sinopharm Group Co. Ltd.'s (HKG:1099) Low P/E No Reason For Excitement](https://longbridge.com/en/news/276085410.md)
*2026-02-17T00:56:45.000Z*
> Sinopharm Group Co. Ltd. (HKG:1099) has a low P/E ratio of 8.4x, indicating potential investor caution due to declining 

### [Policy dividends continue to be released, and the pharmaceutical retail industry welcomes new opportunities for transformation](https://longbridge.com/en/news/275955803.md)
*2026-02-14T00:17:18.000Z*
> Recently, the policy dividends in the pharmaceutical retail industry have been continuously released, and the pace of tr

### [China's biological trivalent influenza virus split vaccine approved for market launch](https://longbridge.com/en/news/274302829.md)
*2026-01-30T11:48:57.000Z*
> On January 30, 2026, the trivalent influenza virus split vaccine developed by China National Pharmaceutical Group's Wuha

### [The newly revised Drug Administration Regulations will be implemented in May, strengthening the growth logic of the pharmaceutical sector](https://longbridge.com/en/news/274063167.md)
*2026-01-29T00:21:14.000Z*
> The newly revised "Regulations for the Implementation of the Drug Administration Law" will take effect on May 15, markin

### [Sinopharm Holdings' subsidiary Sinopharm Accord is expected to see its net profit rise by nearly 90% last year](https://longbridge.com/en/news/273627659.md)
*2026-01-25T23:57:00.000Z*
> Sinopharm Holdings' subsidiary Sinopharm Accord expects net profit to grow by 64.20% to 89.11% in 2025, reaching between

### [SINOPHARM: Sinopharm Accord expects a net profit attributable to the parent company of approximately 1.055 billion to 1.215 billion yuan in 2025, a year-on-year increase of 64.20% to 89.11%](https://longbridge.com/en/news/273622522.md)
*2026-01-25T23:21:03.000Z*
> SINOPHARM expects that Sinopharm Accord's net profit attributable to the parent company in 2025 will reach RMB 1.055 bil